Nazartinib is an orally available, irreversible, third-generation EGFR inhibitor that covalently binds mutant forms of EGFR, including the T790M resistance mutation, and inhibits their signaling. It is being studied in EGFR-mutant non-small cell lung cancer.
Summary written with AI from the sources listed at the end of this page.
At a glance
Also known as
EGF-816
Drug type
Small molecule
Targets
epidermal growth factor receptor (mutant forms, including T790M) (EGFR)
Mechanism
Inhibitor of epidermal growth factor receptor (mutant forms, including T790M) (EGFR)
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.